Prospective Study
Copyright ©The Author(s) 2019.
World J Clin Cases. Aug 26, 2019; 7(16): 2247-2255
Published online Aug 26, 2019. doi: 10.12998/wjcc.v7.i16.2247
Table 1 Baseline demographics and clinical characteristics, n (%)
CharacteristicPatients total (n = 20)
Age (y): Median (range)11.5 (8-16)
Sex, male:10 (50)
Duration (yr) after end of cancer treatment4 (1- 9)
Type of cancer history
ALL17 (85)
Hodgkin Lymphoma2 (10)
Non-Hodgkin Lymphoma1 (5)
Weight (kg): Median (range)37 (24-64.5)
Height (cm): Median (range)137.5 (114-77)
BMI (kg/m2): Median (range)17.7 (14.56-24.89)
HCV RNA (log10 IU/mL): Mean (SD)6.09 (0.72)
HCV RNA ≥ 800000 IU/mL10 (50)
Interferon or ribavirin treatment experience
Naïve:19 (95)
Non-respondent to IFN Rx1 (5)
METAVIR Score by Fibroscan
F117 (85)
F23 (15)
WBCs (× 10⁹/L): Median (range)7.5 (4.1-13.8)
Hemoglobin (g/dL): Median (range)12.05 (10-13.8)
Platelet Count (× 10⁹/L): Median (range)236.5 (66-444)
AST (IU/L): Mean (SD)50.7 (29.4)
ALT (IU/L): Mean (SD)54.3 (40.2)
S. Total Bilirubin (mg/dL): Median (range)0.7 (0.2-1.7)
S. Creatinine (mg/dL): Median (range)0.65 (0.2-0.8)
Table 2 Mean (95% confidence interval) of main biochemical and hematological tests at 3 time points
Variable [Mean (95%CI)]At baselineAt wk 4At wk 12Sig.
Serum. ALT (IU/L)54.3 (35.49– 73.11)19.55 (11.02-28.08)17.45 (15.11-19.80)< 0.05
Serum AST (IU/L)50.7 (36.95-64.45)24.05 (16.40-31.70)19.95 (17.37-22.53)< 0.05
T. Bilirubin (mg/dl)0.66 (0.49-0.82)0.53 (0.42-0.64)0.55 (0.45-0.65)No
S. Creatinine (mg/dl)0.6 (0.52-0.68)0.59 (0.51-0.66)0.61 (0.54-0.68)No
WBCs (× 10⁹/L)7.27 (6.3-8.2)7.62 (6.8-8.5)7.3 (6.5-8.1)No
Hemoglobin (g/dL)12.16 (11.7-12.6)11.9 (11.38-12.35)11.70 (11.13-12.27)No
Platelets (× 10⁹/L)243 (203-283)235.5 (200-271)247.3 (213-281)No